Ariad submits EU MAA for ponatinib and prepares to storm Europe
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has submitted its marketing authorisation application to the European Medicines Agency for ponatinib for resistant or intolerant chronic myeloid leukaemia and Philadelphia-chromosome positive acute lymphoblastic leukaemia. Tim Clackson, the firm's CSO and president of R&D, explained how Ariad will makes it name in the European oncology market and why partnering is not the way to do it.